To our knowledge, this is the first systematic study for the impact of DDR gene mutations on prognosis and response to platinum-based chemotherapy and platinum-based chemotherapy/immunotherapy in NSCLC patients without EGFR and ALK alterations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.